Clemens Zwergel

Dr. Clemens Zwergel

Department of Drug Chemistry and Technologies, Università La Sapienza, Rome, Lazio, Italy
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2019 in Clinical Epigenetics
Verified
Journal Article
Open access
PDF file
RMRoberta Mazzone
Roberta Mazzone
Clemens ZwergelClemens Zwergel
Clemens Zwergel
MAMarco Artico
Marco Artico
STSamanta Taurone
Samanta Taurone
Massimo RalliMassimo Ralli
Massimo Ralli
AMAntonello Mai
Antonello Mai
Epigenetic pathways play a pivotal role in the development and function of the immune system. Over the last decade, a growing body of studies has been published out seeking to explain a correlation between epigenetic modifications and the development of autoimmune disorders. Epigenetic changes, such as DNA methylation, histone modifications, and noncoding RNAs, are involved in the pathogenesis of autoimmune diseases mainly by regulating gene expression. This paper reviews the importance of epigenetic alterations during the development of the most prevalent human autoimmune diseases, such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis (SSc), Sjogren’s syndrome (SS), autoimmune thyroid diseases (AITD), and type 1 diabetes (T1D), aiming to provide new insights in the pathogenesis of autoimmune diseases and the possibility to develop novel therapeutic approaches targeting the epigenome.

22 February 2023 in Green Chemistry
Verified
Journal Article
Open access
PDF file
CCCarola Castiello
Carola Castiello
PJPierre Junghanns
Pierre Junghanns
AMAnnika Mergel
Annika Mergel
Claus JacobClaus Jacob
Claus Jacob
CDChristian Ducho
Christian Ducho
AMAntonello Mai
Antonello Mai
Green chemistry has become a hot topic and the focus of not only many companies but also researchers.

30 May 2017 in Clinical Epigenetics
Verified
Journal Article
Open access
PDF file
RMRoberta Mazzone
Roberta Mazzone
Clemens ZwergelClemens Zwergel
Clemens Zwergel
AMAntonello Mai
Antonello Mai
SVSergio Valente
Sergio Valente
Immune checkpoint factors, such as programmed cell death protein-1/2 (PD-1, PD-2) or cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) receptors, are targets for monoclonal antibodies (MAbs) developed for cancer immunotherapy. Indeed, modulating immune inhibitory pathways has been considered an important breakthrough in cancer treatment. Although immune checkpoint blockade therapy used to treat malignant diseases has provided promising results, both solid and haematological malignancies develop mechanisms that enable themselves to evade the host immune system. To overcome some major limitations and ensure safety in patients, recent strategies have shown that combining epigenetic modulators, such as inhibitors of histone deacetylases (HDACi) or DNA methyltransferases (DNMTi), with immunotherapeutics can be useful. Preclinical data generated using mouse models strongly support the feasibility and effectiveness of the proposed approaches. Indeed, co-treatment with pan- or class I-selective HDACi or DNMTi improved beneficial outcomes in both in vitro and in vivo studies. Based on the evidence of a pivotal role for HDACi and DNMTi in modulating various components belonging to the immune system, recent clinical trials have shown that both HDACi and DNMTi strongly augmented response to anti-PD-1 immunotherapy in different tumour types. This review describes the current strategies to increase immunotherapy responses, the effects of HDACi and DNMTi on immune modulation, and the advantages of combinatorial therapy over single-drug treatment.

4 January 2014 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
SVSergio Valente
Sergio Valente
YLYiwei Liu
Yiwei Liu
MSMichael Schnekenburger
Michael Schnekenburger
Clemens ZwergelClemens Zwergel
Clemens Zwergel
SCSandro Cosconati
Sandro Cosconati
AMAntonello Mai
Antonello Mai
DNA methyltransferases (DNMTs) are important enzymes involved in epigenetic control of gene expression and represent valuable targets in cancer chemotherapy. A number of nucleoside DNMT inhibitors (DNMTi) have been studied in cancer, including in cancer stem cells, and two of them (azacytidine and decitabine) have been approved for treatment of myelodysplastic syndromes. However, only a few non-nucleoside DNMTi have been identified so far, and even fewer have been validated in cancer. Through a process of hit-to-lead optimization, we report here the discovery of compound 5 as a potent non-nucleoside DNMTi that is also selective toward other AdoMet-dependent protein methyltransferases. Compound 5 was potent at single-digit micromolar concentrations against a panel of cancer cells and was less toxic in peripheral blood mononuclear cells than two other compounds tested. In mouse medulloblastoma stem cells, 5 inhibited cell growth, whereas related compound 2 showed high cell differentiation. To the best of our knowledge, 2 and 5 are the first non-nucleoside DNMTi tested in a cancer stem cell line.

19 October 2018 in The Chemical Record
Verified
Journal Article
Closed access
PDF file
RFRossella Fioravanti
Rossella Fioravanti
GSGiulia Stazi
Giulia Stazi
Clemens ZwergelClemens Zwergel
Clemens Zwergel
SVSergio Valente
Sergio Valente
AMAntonello Mai
Antonello Mai

18 June 2020 in Frontiers in Chemistry
Verified
Journal Article
Open access
PDF file
EBElisabetta Di Bello
Elisabetta Di Bello
Clemens ZwergelClemens Zwergel
Clemens Zwergel
AMAntonello Mai
Antonello Mai
SVSergio Valente
Sergio Valente
Numerous and different types of cancers possess the dysregulation of the mevalonate pathway as a common feature. Statins, traditionally applied in cardiovascular diseases to reduce lipid levels, subsequently have been discovered to exhibit anti-cancer activities also. Indeed, statins influence proliferation, migration, and survival of cancer cells by regulating crucial signaling proteins, such as Rho, Ras, and Rac. Recently, several studies have demonstrated that simvastatin, fluvastatin, and lovastatin are implicated in different pathways that enhance the survival time of patients with cancer under treatment in combination with antineoplastic agents. In this minireview, we present an overview of the most important studies conducted regarding the use of statins in cancer therapy up to date.